Skip to Main Content
Skip Nav Destination

Editorial Board

Chair of the Editorial Board

Professor Mark Lemmon

Affiliation: Department of Pharmacology, and Cancer Biology Institute, Yale University School of Medicine, New Haven, CT, USA
Role: Chair of the Editorial Board
Keywords: epidermal growth factor receptor, protein structure, receptors, cancer, membranes, endocytosis, crystallography, phosphoinositides, phosphorylation
Subject Areas: Signalling Pathways and Processes

Biography: Mark Lemmon grew up in Norwich and received his BA in Biochemistry at Oxford (Hertford College) in 1988. After his PhD with Don Engelman at Yale as a HHMI Predoctoral Fellow he was a Damon Runyon Postdoctoral Fellow with Joseph Schlessinger at NYU Medical Center in Manhattan, studying mechanisms of receptor tyrosine kinase signaling and phospholipid-binding domains. In 1996, Mark was appointed as Assistant Professor in the Department of Biochemistry and Biophysics at the University of Pennsylvania Perelman School of Medicine, where he stayed for 19 years - ultimately as department Chair. He then moved to Yale University School of Medicine in 2015, where he is now the David A. Sackler Professor of Pharmacology, Co-Director of the Yale Cancer Biology Institute, and Associate Director (Basic Science) of Yale Cancer Center. Mark's laboratory links studies of mechanistic and structural aspects of signalling by growth factor receptors (especially EGF receptor) in normal and disease states with cellular and clinical studies. His best known recent contributions include explanation of the structural bases for allostery and biased agonism in the EGF receptor and exploiting structural understanding to understand and target aberrant growth factor receptor signalling in cancer. Mark was awarded the Dorothy Crowfoot Hodgkin Award of the Protein Society in 2012 and was elected as a Fellow of the Royal Society in 2016.

Associate Editors

Dario Alessi

Affiliation: MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee
Role: Associate Editor
Keywords: extracellular signal-regulated kinases, insulin signalling protein tyrosine phosphatases inositol polyphosphates inositide signalling, mitogen-activated protein kinase 8
Subject Area: Signalling

Biography: Dario’s research focuses on unravelling the roles of poorly characterised components which regulate protein phosphorylation or ubiquitylation pathways that are linked to human disease. Dario obtained a BSc (1988) and PhD (1991) from the University of Birmingham, United Kingdom. He carried out postdoctoral at the University of Dundee from (1991 to 1997), where he became fascinated by protein kinases and how they are regulated by insulin, growth factors and other extracellular signals that control almost all aspects of cell biology. In 1997 Dario became a program leader in the MRC Protein Phosphorylation Unit, where he was appointed as ts Director in 2012. Dario has contributed to our understanding of several disease relevant signal transduction pathways including PDK1 (diabetes and cancer), LKB1 (cancer), WNKs (blood pressure). Much of Dario’s current work is focused on understanding LRRK2 and how mutations in this enzyme cause Parkinson’s disease. Dario’s work has contributed to approaches (LRRK2 kinase assay, LRRK2 Ser935 dephosphorylation assay, Rab phosphorylation assays) that have facilitated the development of inhibitors against LRRK2 that may be useful for the treatment of Parkinson’s disease. Dario’s lab contributed to the discovery and validation of the first physiological substrates for the Parkinson’s disease LRRK2 protein kinase to be identified showing that LRRK2 directly phosphorylates a subset of the Rab GTPases on a residue lying within the middle of the effector interacting-switch II domain. Dario in collaboration with the Michael J Fox Foundation to better interrogate and understand LRRK2 biology and how it is impacted by mutations, environment and inhibitors that are being developed and assessed. Dario also serves as the Director of the Dundee Signal Transduction Therapy Unit. This is a unique collaboration between scientists at the University of Dundee and pharmaceutical companies, dedicated to accelerating the development of specific inhibitors and chemical probes that target the protein phosphorylation and ubiquitylation system for the treatment of disease, as well as for the study of cell signalling. Dario has published around 260 papers and has a h-index of 129.

Jonathan Backer

Affiliation: Albert Einstein College of Medicine, Bronx, NY, USA
Keywords: signal transduction, PI 3-kinase, cancer, metastasis, motility, vesicular trafficking
Subject area: Signalling Pathways and Processes

Biography: Jon Backer received his M.D. from Harvard Medical School in 1987, where he worked with Paulo Dice on what is now called chaperone-mediated autophagy, and with Lennie Dawidowicz on lipid trafficking. He was a postdoctoral fellow with Morris White and Ron Kahn and the Joslin Diabetes Center, where he worked on insulin signaling and demonstrated that PI 3-kinase binds to and is activated by tyrosine phosphorylated IRS-1. He joined the Department of Molecular Pharmacology at Albert Einstein College of Medicine in 1993, and he is currently the Williams S. Lasdon Professor and Chair of the department. His research has focused on the mechanisms of PI 3-kinase activation by growth factor receptors and GPCRs, and the role of PI 3-kinases in tumorigenesis, metastasis, vesicular trafficking, and metabolism.

Ben Black

Affiliation: Department of Biochemistry & Biophysics, University of Pennsylvania, Philadelphia, PA, USA
Keywords: Chromatin structure, nucleosomes, histones, centromeres, kinetochores, hydrogen/deuterium exchange-mass spectrometry
Subject Areas: Gene Expression and Regulation

Biography: Following undergraduate studies at Carleton College, Ben Black did a Ph.D. dissertation at the University of Virginia on pathways for nuclear protein export in the lab of Bryce Paschal. After a four-year postdoctoral fellowship with Don Cleveland at UCSD in the Ludwig Institute for Cancer Research, Ben started his own group at UPenn to continue the work he had started in the area of chromosome biology. Perhaps his best known work as an independent investigator is uncovering the physical basis for how nucleosomes containing the histone variant, CENP-A, epigenetically mark centromere location on the chromosome; and further, for helping elucidate how this nucleosome can seed new centromere assembly and maintain centromere location through a cell cycle-coupled self-propagation mechanism ultimately required to guide faithful chromosome inheritance. He has been recognized for his work with a fellowship from the American Cancer Society, a Career Award in the Biomedical Sciences from the Burroughs Wellcome Fund, a Rita Allen Foundation Scholar Award, and the Michael S. Brown New Investigator Award. 

A. Clay Clark

Affiliation: Department of Biology, University of Texas at Arlington, Arlington, USA
Keywords:Protein allostery, fluorescence emission, crystallography, enzymology, thermodynamic studies, apoptosis
Subject area: Molecular structure and function

Biography: Clay Clark received a BS in Biology from the University of Georgia, an MS in Biology from the University of San Francisco, and a PhD in Biochemistry from Texas A&M University under the direction of Dr Thomas O. Baldwin. During his doctoral studies, he examined the protein folding properties of bacterial luciferase. He then trained as a postdoctoral associate with Dr Carl Frieden at Washington University School of Medicine where he examined the folding of DHFR and its interactions with the chaperonin GroEL. He moved to Raleigh, North Carolina, in 1999 as an Assistant Professor of Biochemistry, and he currently is Professor and Chair of Biology at the University of Texas at Arlington. His research focuses on the allosteric control and evolution of caspases.

Michael Duchen

Affiliation: Department of Physiology and Mitochondrial Biology Group, University College London, London, UK
Keywords: Mitochondria, calcium signalling, autophagy, fluorescence microscopy and imaging
Subject Area: Energy Processes

Biography: Michael was born in South Africa, moving to the UK in 1960. He studied Physiology and Medicine in Oxford, 1971-75, then moved to St George's Hospital Medical School to complete his clinical training, graduating 1978. He worked in clinical medicine in junior hospital appointments 1978-1981 including a period working at a rural hospital in the Transkei, South Africa. He moved to the UCL Department of Physiology to embark on PhD studies 1981-1984 with Tim Biscoe as supervisor and mentor. He has stayed at UCL Physiology (now the Department of Cell and Developmental Biology) ever since, first as a Royal Society University Research Fellow, then as Reader and Professor. His early research was electrophysiological with an interest in neurotransmitter receptor biology, but he became interested first in the influence of cell metabolism on excitability and then increasingly fascinated by mitochondrial biology, in the dialogue between cell signalling pathways and mitochondria, in the roles of mitochondria in disease and ultimately in the question of whether mitochondrial pathways represent viable therapeutic targets in a variety of disease states.

Patrick Eyers

Affiliation: Department of Biochemistry and Systems Biology, University of Liverpool, Liverpool, UK
Keywords: Protein phosphorylation; kinase; phosphatase; pseudokinase; pseudoenzyme; redox regulation; cell cycle; cell signalling; phosphoproteomics; sulfation; desulfation; small molecule; inhibitor
Subject Areas: Cell signalling, phosphorylation; cell cycle; post translational modifications; kinomes, drug-resistance and kinome

Biography: Pat Eyers is Professor of Cell Signalling, and Head of the Department of Biochemistry and Systems Biology, at the University of Liverpool. He runs a multidisciplinary research lab that seeks to answer fundamental questions pertaining to the mechanisms of cell signalling. After completing a PhD with Sir Philip Cohen at the University of Dundee and 4 years of postdoctoral research in the USA with the late Jim Maller, he set up his laboratory in the UK with an MRC Career Development Fellowship in 2005. His current interests include all aspects of protein phosphorylation and sulfation, analysis of protein kinase and sulfotransferase regulation, pseudokinases and pseudoenzymes and kinome-wide mechanisms of acquired drug resistance in cells. In addition, he uses the tools of chemical biology to probe intracellular signalling mechanisms in a variety of cell models, integrating kinomics, phosphoproteomics and redox-regulated signalling. His work has led to several findings relevant to kinome-based analysis, including the co-discovery of the gatekeeper residue in Ser/Thr kinases (1997-2000), the analysis of the cell cycle by mitotic kinases (2000-2010), conserved mechanisms of drug-resistance in the human kinome (2009-2019) and his group's present work on redox regulation of protein kinases, pseudokinases and other pseudoenzymes found across the kingdoms of life.

Christine Foyer

Affiliation: Centre for Plant Sciences, School of Biosciences, University of Birmingham, UK
Keywords: oxidation-reduction, antioxidants, mitochondria, chloroplasts, carbon metabolism, phytohormones
Subject Areas: Plant Biology; Energy Processes

Biography: Christine Foyer is Professor of Plant Sciences at the University of Birmingham UK. She obtained her PhD in 1977 from Kings College, London. Christine held senior appointments at a number of leading Institutions in the UK and in Europe. Christine is member of the Board of Directors of the American Society of Plant Biologists and President Elect of the Association of Applied Biologists. She is also a member of a number of Institutional Advisory Boards and is currently the Chair for the FWO grant review panel BIO1 in Belgium, and a Chair of one of the ERC Consolidator Grant Panels. Christine is a specialist in plant metabolism, particularly redox regulation and signalling. Christine is ranked within the top 1% most cited works (Web of Science) for the subject field and year of publication, earning a mark of Exceptional Impact. 

Jennifer Kohler

Affiliation: Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, USA
Keywords: Chemical biology, glycobiology, membrane protein 
Subject area: Molecular structure and function

Biography: Jennifer Kohler completed her undergraduate degree in Chemistry at Bryn Mawr College. Her PhD studies, focused on the kinetics of protein-DNA interactions, were conducted in the laboratory of Professor Alanna Schepartz, in the Chemistry Department at Yale University. From 2000 to 2004, Jennifer was an American Cancer Society postdoctoral fellow with Professor Carolyn Bertozzi at the University of California, Berkeley. Research in the Kohler laboratory focuses on understanding the roles of glycoconjugates in a variety of biological systems.

Tatiana Kutateladze

Affiliation: University of Colorado School of Medicine, Anschutz Medical Campus, USA
Role: Associate Editor
Keywords: epigenetic and chromatin remodelling, signaling, posttranslational histone modifications

Subject area: Structural biology and Epigenetics
Biography: Tatiana received her Ph.D. degree in chemistry from the Moscow State University and completed her postdoctoral training in biochemistry and structural biology in the US. She is currently a Professor in the Department of Pharmacology at the University of Colorado School of Medicine. Her research interests include studying epigenetic and chromatin remodeling signaling, posttranslational histone modifications and the role of epigenetic misregulations in human diseases. Tatiana’s laboratory applies high field NMR spectroscopy and X-ray crystallography to obtain atomic-resolution structures of chromatin-binding proteins involved in transcriptional regulation and DNA damage repair. Among their major achievements, the Kutateladze’s lab is credited with determining molecular bases underlying methyllysine and acyllysine recognition by a large number of epigenetic readers.

Sheng-Cai Lin

Affiliation: School of Life Sciences, Xiamen University, Xiamen, China
Keywords: AMPK, Axin, mTORC1, lysosomal regulation of metabolic control, fat synthesis
Subject Areas: Metabolism; Signalling Pathways and Processes

Biography: Shengcai obtained his Ph.D. in Biochemistry from the University of Texas Southwestern Medical Center at Dallas. He finished his postdoctoral training at the Howard Hughes Medical Institute, University of California at San Diego. During his postdoctoral training, he cloned the receptor for growth hormone releasing factor, which is a G-protein coupled receptor, and identified types of dwarfism associated with dysfunction of the receptor. Afterwards, he worked on the regulators of G-protein signalling (RGS proteins), and became interested in the RGS-domain protein called AXIN, standing for inhibitor of axis. AXIN has been shown to regulate a number of important biological processes, including the JNK/MAPK pathway and tumor suppressor p53 signaling. His most prominent discovery is with the identification of mechanisms for cellular AMPK activation, revealing that AXIN serves as a bridge for LKB1 to phosphorylate AMPK, and later that AMPK activation occurs on the surface of the lysosome. Shengcai continues to focus on the regulation of AMPK and its role in metabolic control.

James M Murphy

Affiliation: Walter and Eliza Hall Institute of Medical Research
Keywords: structural biology, X-ray crystallography, SAXS, NMR, biophysics, proteins, enzymes, kinase, pseudokinase, pseudoenzyme, signal transduction, cell signalling, cytokine signaling, JAK kinases, cell death, necroptosis, programmed necrosis, MLKL, RIPK1, RIPK3
Subject area: Molecular structure and function; Signalling Pathways and Processes         

Biography: James Murphy completed his undergraduate studies at the University of Canterbury, NZ, and PhD at the Australian National University under the supervision of David Ollis and Ian Young in 2003. As a CJ Martin Fellow of the National Health and Medical Research Council of Australia, he developed an interest in kinases and pseudokinases as a postdoc with Tony Pawson and Frank Sicheri (Toronto). Subsequently, he established his lab at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, to dissect the signaling functions of the “zombie” cousins of protein kinases, the pseudokinases, using structural, biochemical, cellular and in vivo approaches. Much of his lab’s attention has been applied to understanding one such zombie protein, MLKL, and how it is activated by the kinase, RIPK3, to initiate cell death via the necroptosis pathway. Since 2019, James has headed the Inflammation Division at the Walter and Eliza Hall Institute.  

Hayley Newton

Affiliation: University of Melbourne, The Peter Doherty Institute for Infection and Immunity 
Keywords: Bacterial pathogenesis, vesicular trafficking
Subject area: Cell Biology         

Biography: Dr Hayley Newton completed her PhD at Monash University, Australia, investigating the virulence of Legionella pneumophila. She then completed a post-doctoral fellowship within the laboratory of Professor Craig Roy at Yale University. Here she worked extensively to develop an understanding of the pathogenesis of the intracellular bacterial pathogen Coxiella burnetii. During this period, Hayley developed pioneering techniques to genetically manipulate Coxiella burnetii and demonstrated that the Dot/Icm type IV secretion system is an essential virulence determinant. These findings have led to a significant advancement in our understanding of this mysterious intracellular pathogen. Hayley moved to the Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute in 2013. Here she has established a research program examining the virulence strategies of intracellular bacterial pathogens with a focus on both uncovering the molecular mechanisms of pathogenesis and using these intracellular pathogens as tools to learn new things about human cell function. Hayley currently holds a teaching/research academic position and is the Co-Theme leader for Host-Pathogen Interactions for the Doherty Institute.  

Katrin Rittinger

Affiliation: Molecular Structure of Cell Signalling Laboratory, The Francis Crick Institute, London, UK 
Keywords: Ubiquitination, protein structure, protein structure/assembly, ubiquitin ligases, protein signalling modules/scaffolds, enzyme structure-function
Subject Areas: Molecular structure and function

Biography: Katrin Rittinger studied Chemistry at the University of Heidelberg and carried out her Ph.D. with Roger Goody at the Max-Planck Institute for Medical Research in Heidelberg. In 1996, she received an EMBO Long-Term and subsequently a Marie-Curie Fellowship to move to the MRC National Institute for Medical Research (NIMR) in London to work with Guy Dodson and Alastair Aitken on the structural basis of the interaction between 14-3-3 proteins and phosphorylated target proteins. In parallel she became interested in members of the Rho-family of GTPases and helped to elucidate the mechanism of action of GTPase-activating proteins (GAPs). In 2000 she set up her own independent group at the MRC-NIMR studying the molecular basis of signalling processes that are regulated by Rho family GTPases. More recently, she has developed an interest in the ubiquitination-dependent regulation of immune signalling processes. Her group has recently moved to the Francis Crick Institute in London. 

Stanislav Y. Shvartsman

Affiliation: Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, USA
Keywords: biochemical networks, signal transduction, cell regulation, computational modeling
Subject Areas: Systems Biology

Biography: Stanislav Shvartsman was born in Odessa, Ukraine, and studied physical chemistry and chemical engineering at Moscow State University, the Technion-Israel Institute of Technology, and Princeton University. In 2001, after postdoctoral work at the Massachusetts Institute of Technology, he founded his own lab at Princeton's Lewis-Sigler Institute for Integrative Genomics. His research combines genetic, imaging, and biophysical tools to study dynamics of embryonic development. In 2019, he joined the Flatiron Research Institute in NYC, as a group leader in the Center for Computational Biology. The Princeton and Flatiron groups are highly integrated in their work and approaches.

Anabella Srebrow

Affiliation: Instituto de Fisiología, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
Keywords: pre-mRNA processing, splicing, spliceosome, RNA, RNA-binding proteins, post-translational modifications, protein SUMOylation, SUMO conjugation pathway, signal transduction
Subject Areas: Gene Expression and Regulation

Biography: Anabella Srebrow received a MS in Biology (1992) and a PhD in Biology (1997) from the University of Buenos Aires (Argentina) after conducting her PhD thesis work at The Lawrence Berkeley National Laboratory (Berkeley, CA, US) under the supervision of Dr Mina Bissell. During her doctoral training, she focused in the regulation of hox gene expression along mouse mammary gland differentiation. During 1998 and 1999, she trained as a postdoctoral fellow with Dr Alberto Kornblihtt at the School of Exact and Natural Sciences of the University of Buenos Aires (FCEyN-UBA) and the Argentina National Research Council (CONICET), studying alternative splicing regulation by extracellular cues in the context of cell-cell and cell-ECM interaction. Since 2000, she has held a research position at CONICET and in 2004 she set up her own independent group at IFIBYNE-UBA-CONICET. In 2010 she was appointed as an Adjunct Professor at the School of Exact and Natural Sciences of the University of Buenos Aires where she teaches cell and molecular biology. Her laboratory studies the connection between the splicing machinery and the SUMO conjugation pathway in mammalian cells, and also the impact of dengue virus infection on host cell pre-mRNA processing.

Gregory Steinberg

Affiliation: Department of Medicine, McMaster University, Hamilton, Canada
Keywords: Fatty acids/acylglycerols, lLipid metabolism, mitochondria, oxidative phosphorylation, atherosclerosis/cardiovascular disease, diabetes 
Subject Area: Metabolism

Biography: Gregory Steinberg completed his B.Sc. (1998) and Ph.D. (2002) at the University of Guelph in Canada. His Ph.D. studies in the laboratory of Professor David Dyck involved studying the role of leptin in muscle. From 2002 to 2006 Greg was a postdoctoral fellow with Professor Bruce Kemp at St Vincent’s Institute of Medical Research where he studied the role of the AMP-activated protein kinase (AMPK). In 2006 he started his academic career as Lecturer, Senior Research Fellow and Head of Metabolism at St Vincent’s Institute and the University of Melbourne. In 2009 he returned to Canada where he is currently a Professor and Canada Research Chair in the Department of Medicine at McMaster University. His laboratory's main interests involve studying how obesity, nutrition and exercise influence health with a major focus on inflammation and lipid metabolism.

Cathy Tournier

Affiliation: University of Manchester, UK
Keywords: mitogen-activated protein kinases, gene expression, tumour biology
Subject Area: Mechanisms of Disease

Biography: Cathy Tournier was awarded a PhD in 1996 by the University of Paris XI in France for her work on the regulation of mitogen-activated protein kinases (MAPK) in astrocytes. She then trained as a postdoctoral fellow in the laboratory of Professor Roger J Davis at the University of Massachusetts Medical School in the USA, where she discovered that genetically modified mouse models constituted powerful tools to decipher cellular and molecular bases of biological processes. In July 2000, she was appointed as a lecturer in the Faculty of Life Sciences at the University of Manchester. She was promoted to Senior Lecturer in 2012. Her research focuses on deciphering abnormal signal transduction via MAPKs in diseases.

Bart Vanhaesebroeck

Affiliation: University College London Cancer Institute, London, UK
Keywords: Signal transduction, PI 3-kinase, growth factors, oncology, drug development, cancer
Subject Area: Chemical Biology

Biography: Following a Ph.D. from the Laboratory of Molecular Biology at Ghent University (Belgium), BV carried out postdoctoral studies at the Ludwig Institute for Cancer Research at University College London (UCL). BV’s research focuses on PI 3-kinase (PI3K) enzymes, which are key regulators of cell signalling. PI3K signalling is often deregulated in cancer and is also important amongst other in immunity and metabolism. BV’s laboratory aims to understand the roles and mechanism of action of the PI3K family members and to explore their potential as drug targets for cancer and other diseases. BV’s team identified the PI3Kdelta isoform as a target in immunity, inflammation and haematological malignancies, which led to extensive efforts to create drug against PI3Kdelta. In 2014, a PI3Kdelta inhibitor (Idelalisib - Gilead) was approved for the treatment of specific blood cancers. Our recent discovery that inhibition of PI3Kdelta leads to immuno-stimulation in cancer (Nature 2014:510:407) potentially widens the use of PI3Kdelta inhibitors to cancer immunotherapy, a concept that is currently being tested in clinical trials. BV has been an Associate Editor of the Biochemical Journal since 2003. He is an elected member of EMBO and of the UK Academy of Medical Sciences.

Ming-Wei Wang

Affiliation: Shanghai Institute of Materia Medica, Chinese Academy of Sciences/Shanghai Medical College, Fudan University, Shanghai, China
Keywords: Chemistry, bioactivity, drug screening
Subject area: Chemical Biology

Biography: Following medical practices in Shanghai, Dr. Ming-Wei Wang obtained his Ph.D. degree from University of Cambridge in 1989. He worked for a couple of US-based biotech companies a year later and served as a consultant to Merck and UNDP on China-related projects in the mid-1990’s. Thereafter, he was engaged in various entrepreneur activities. Dr. Wang joined the faculty of Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2001 and became Director of the National Center for Drug Screening in 2003. In 2004, he was named by Shanghai Pudong New District Government as a Senior Business Advisor. He founded the Chinese National Compound Library and has been its first director since 2012. Dr. Wang was appointed as Dean, School of Pharmacy, Fudan University in 2015. His research achievements include discovery of a non-peptidic glucagon-like peptide-1 receptor agonist Boc5 effective in vivo, determination of the 3-D structures of human glucagon receptor, glucagon-like peptide-1 receptor, parathyroid hormone receptor-1 and growth hormone-releasing hormone receptor, elucidation of the insulinotrophic effect of insulin-like peptide 5 and identification of the link of GPR160 (an orphan GPCR) and prostate cancer.

Tao Xu

Affiliation: Institute of Biophysics, Chinese Academy of Sciences, Beijing, Chin
Keywords: Trafficking, exocytosis, endocytosis, pancreatic beta cell, imaging techniques
Subject Area: Cell Biology

Biography: Tao Xu received his BS (Engineering) from Huazhong University of Science and Technology, and his PhD in Biophysics at the Institute of Biophysics and Biochemistry, Huazhong University of Science and Technology. From 1996 to 1999 he undertook postdoctoral work with Erwin Neher in the Department of Membrane Biophysics at the Max-Planck Institute for Biophysical Chemistry in Goettingen, and then spent 2 years with Bertil Hille at the Department of Physiological and Biophysics at the University of Washington in Seattle. In 2000 he returned to the Institute of Biophysics and Biochemistry at Huazhong University as a Professor. In 2003 he moved to the Institute of Biophysics, Chinese Academy of Sciences, in Beijing, and was appointed as the Director there in 2007. His research interests focus on identifying molecular mechanisms of membrane trafficking and developing super-resolution imaging techniques for biological research.

Chiara Zurzolo

Affiliation: Trafic Membranaire et Pathogenèse, Institut Pasteur, Paris, France
Keywords: Glycoproteins/glycolipids, Golgi, lysosomes, protein sorting, prion-like proteins, trafficking, targeting, secretion
Subject Area: Cell Biology

Biography: Professor Chiara Zurzolo MD, PhD is currently Director of the Membrane Trafficking and Pathogenesis Unit, and Director of the Department of Cell Biology and Infection at the Pasteur Institute, Paris, France. She earned a Medical Degree and a PhD at Naples University Federico II where she also specialized in Oncology. She spent 3 years as postdoc at the Cornell University Medical School in NYC, where she uncovered some of the mechanisms of apical protein sorting in polarized epithelial cells. In 1995 she became Assistant Professor in Cell and Molecular Biology at Naples University and in 2000 Associate Professor. In 2003 she joined the Pasteur Institute as group leader and in 2014 became Director of the Cell Biology Department. Her research interests are focused on understanding the role of protein trafficking in diseases in epithelial and neuronal cells. Currently part of her laboratory focuses on understanding how prions (and prion-like proteins underlying other neurodegenerative diseases) misfold inside the cells and how they spread from one cell to another. She discovered that tunnelling nanotubes (TNTs) allow the intercellular passage of prions, and she proposed that these structures are involved in the spreading of different neurodegenerative diseases in the brain. In 2015, Professor Zurzolo was elected an EMBO Member.

Editorial Board members

  • Josephine Adams (University of Bristol, Bristol, UK)
  • Hugo Armelin (University of Sao Paulo, Sao Paulo, Brazil)
  • James Bear (University of North Carolina School of Medicine, Chapel Hill, USA)
  • Lawrence Boise (Emory School of Medicine, Miami, USA)
  • Jonathan Blank (Cambridge, USA)
  • Juan Bolanos (University of Salamanca, Salamanca, Spain)
  • Maria Bogoyevitch (University of Melbourne, Parkville, Australia)
  • Kakoli Bose (Tata Memorial Centre, Navi Mumbai, India)
  • Sarah Bray (University of Cambridge, Cambridge, UK)
  • Stefan Broer (Australian National University, Canberra, Australia)
  • Paul Brookes (University of Rochester Medical Center, Rochester, USA)
  • Robert Casero, Jr (The Johns Hopkins University School of Medicine, Baltimore, USA)
  • Leonid Chernomordik (National Institutes of Health, Bethesda, USA)
  • Jianmin Cui (Washington University in St Louis, St Louis, USA)
  • Victor Davidson (University of Central Florida, Orlando, USA)
  • Michael Davies (University of Copenhagen, Copenhagen, Denmark)
  • Catherine Day (University of Otago, Dunedin, New Zealand)
  • Lakshmi Devi (Mount Sinai School of Medicine, New York, USA)
  • Jane Endicott (Northern Institute for Cancer Research, Newcastle upon Tyne, UK)
  • Fabienne Foufelle (UMRS 1138 INSERM, Paris, France)
  • Christian Frezza (University of Cambridge, Cambridge, UK)
  • Mark Hampton (University of Otago Christchurch, Christchurch, New Zealand)
  • Andrew Hanson (University of Florida, Gainesville, USA)
  • Jeanne Hardy (University of Massachusetts, Amherst, USA)
  • Phillip Hawkins (The Babraham Institute, Cambridge, UK)
  • Peter Hedden (Rothamsted Research Institute, Harpenden, UK)
  • Neil Hogg (Medical College of Wisconsin, Milwaukee, USA)
  • Anne Imberty (CERMAV-CNRS, Grenoble, France)
  • David Jans (Monash University, Monash, Australia)
  • Joseph Jez (Washington University in St Louis, St Louis, USA)
  • Kiaran Kirk (The Australian National University, Canberra, Australia)
  • Sunghoon Kim (Seoul National University, Seoul, South Korea)
  • Alicia Kowaltowski (University of Sao Paulo, Sao Paulo, Brazil)
  • Zachary Knight (University of California San Francisco, San Francisco, USA)
  • Susan Lees-Miller (University of Calgary, Calgary, Canada)
  • Steve Ley (The Francis Crick Institute, London, UK)
  • Martin Lowe (University of Manchester, Manchester, UK)
  • Kristen Lynch (University of Pennsylvania, Philadelphia, USA)
  • Neil McDonald (The Francis Crick Institute, London, UK)
  • Gerry Melino (Leicester University, Leicester, UK)
  • Tony Miller (John Innes Centre, Norwich, UK)
  • Greg Moorhead (University of Calgary, Calgary, Canada)
  • Simon Morley (University of Sussex, Brighton, UK)
  • Martina Muckenthaler (University of Heidelberg, Heidelberg, Germany)
  • James Murphy (Walter and Eliza Hall Institute of Medical Research, Parkville, Australia)
  • James Naismith (University of St Andrews, St Andrews, UK)
  • Angel Nebrada (Institute for Research in Biomedicine Barcelona, Barcelona, Spain)
  • Wataru Ogawa (Kobe University Graduate School of Medicine, Kobe, Japan)
  • Masato Okada (Osaka University, Osaka, Japan)
  • Klaus Okkenhaug (University of Cambridge, Cambridge, UK)
  • Robert Parton (The University of Queensland, Queensland, Australia)
  • Bernard Payrastre (Inserm - Unite de recherche U1048, Toulouse, France)
  • Dehua Pei (Ohio State University, Columbus, USA)
  • William Plaxton (Queen's University, Kingston, Canada)
  • Sreenivasan Ponnambalam (University of Leeds, Leeds, UK)
  • Christopher Proud (South Australian Health and Medical Research Institute, Adelaide, Australia)
  • Barry Potter (University of Oxford, Oxford, UK)
  • Andrew Quest (University of Chile, Chile)
  • Mary Roberts (Boston College, Boston, USA)
  • Brad Rothberg (Temple University School of Medicine, Philadelphia, USA)
  • Paul Saftig (Christian Albrecht University Kiel, Kiel, Germany)
  • Kei Sakamoto (University of Copenhagen, Copenhagen, Denmark)
  • Jose Sanchez-Ruiz (Universidad de Granada, Granada, Spain)
  • Karin Schumacher (University of Heidelberg, Heidelberg, Germany)
  • Paul Schumacker (Northwestern University Feinberg School of Medicine, Chicago, USA)
  • Louise Serpell (University of Sussex, Sussex, UK)
  • Solange Serrano (Instituto Butantan, Sao Paulo, Brazil)
  • Hitoshi Shimano (University of Tsukuba, Tsukuba, Japan)
  • Jonathan Slack (University of Bath, Bath, UK)
  • Dirk Snyders (University of Antwerpen, Antwerp, Belgium)
  • W. Marshall Stark (University of Glasgow, Glasgow, UK)
  • Vincent Tagliabracci (UT Southwestern Medical Center, Dallas, USA)
  • Claire Thornton (King's College, London, UK)
  • Kostas Tokatlidis (University of Glasgow, Glasgow, UK)
  • Claudia Tomes (Universidad Nacional de Cuyo, Mendoza, Argentina)
  • Helle Ulrich (Institute of Molecular Biology, Mainz, Germany)
  • Sylvie Urbe (University of Liverpool, Liverpool, UK)
  • Michelle West (University of Sussex, Brighton, UK)
  • Spencer Whitney (Australian National University, Canberra, Australia)
  • Donghai Wu (Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China) 
  • Ian Zachary (University College London, London, UK)
Close Modal

or Create an Account

Close Modal
Close Modal